Francesco Tonelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Francesco Tonelli has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Maria Luisa Brandi
Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS , 20132 Milan
7 shared publications - Stefano Scaringi
Department of Clinical and Experimental Medicine, University of Florence, Largo Brambilla 3, 50134 Firenze, Italy
7 shared publications Ferdinando Ficari
5 shared publications- Francesco Giudici
Department of Experimental and Clinical Medicine, University of Florence, 50100 Florence, Italy
5 shared publications Geri Fratini
4 shared publications- Giacomo Batignani
Department of Experimental and Clinical Medicine, AOU Careggi, 50134 Florence, Italy
4 shared publications
Latest Publications
- Open Access
Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
We reviewed the literature about entero-pancreatic neuroendocrine tumors in Multiple Endocrine Neoplasia type 1 syndrome (MEN1) to clarify their demographic features, localization imaging, practice, and appropriate therapeutical strategies, analyzing the current approach to entero-pancreatic neuroendocrine tumors in MEN1. Despite the fact that hyperparathyroidism is usually the first manifestation of MEN1, the penetrance of these tumors is similar. They are characterized by multiplicity of lesions, variable expression of the tumors, and propensity for malignant degeneration. Both the histological type and the size of MEN1 neuroendocrine tumors correlate with malignancy. Monitoring of pancreatic peptides and use of imaging exams allow early diagnosis and prompt surgical treatment, resulting in prevention of metastatic disease and improvement of long-term survival. Surgery is often the treatment of choice for MEN1-neuroendocrine tumors. The rationale for surgical approach is to curtail malignant progression of the disease, and to cure the associated biochemical syndrome, should it be present.
Open AccessGastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
We reviewed the literature about entero-pancreatic neuroendocrine tumors in Multiple Endocrine Neoplasia type 1 syndrome (MEN1) to clarify their demographic features, localization imaging, practice, and appropriate therapeutical strategies, analyzing the current approach to entero-pancreatic neuroendocrine tumors in MEN1. Despite the fact that hyperparathyroidism is usually the first manifestation of MEN1, the penetrance of these tumors is similar. They are characterized by multiplicity of lesions, variable expression of the tumors, and propensity for malignant degeneration. Both the histological type and the size of MEN1 neuroendocrine tumors correlate with malignancy. Monitoring of pancreatic peptides and use of imaging exams allow early diagnosis and prompt surgical treatment, resulting in prevention of metastatic disease and improvement of long-term survival. Surgery is often the treatment of choice for MEN1-neuroendocrine tumors. The rationale for surgical approach is to curtail malignant progression of the disease, and to cure the associated biochemical syndrome, should it be present.
- 1 March 2012
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 55 (3) , 322-329
Ileal Pouch Adenomas and Carcinomas After Restorative Proctocolectomy for Familial Adenomatous Polyposis
Restorative proctocolectomy and IPAA has become the treatment of choice in familial adenomatous polyposis. However, several cases of adenomas and carcinomas arising in the ileal pouch were reported. The aim of this study was to evaluate the prevalence and natural history of ileal pouch adenomas and the development of carcinomas in patients with restorative proctocolectomy for familial adenomatous polyposis. We prospectively studied patients who underwent IPAA during the past 20 years at the surgical unit of the University of Florence in Italy. We investigated the extent of the risk and the factors that are involved in the development of neoplastic changes of the pouch. Furthermore, because it is not entirely clear when and how polyps should be treated, we have revised our modality of treatment for this unusual pathology. Sixty-nine patients with familial adenomatous polyposis underwent restorative proctocolectomy. In 66 patients, handsewn ileoanal anastomosis with anal canal mucosectomy was performed. After surgery, all patients underwent endoscopic surveillance. After 10 years of follow-up, 1 ileal pouch adenoma was found in 64.9% of restorative proctocolectomy patients, and ileal pouch carcinomas occurred in 2 patients (29 and 59 years old), 3 and 11 years after restorative proctocolectomy. The number of colonic adenomatous polyps influenced the occurrence of pouch adenomas. No patients with 1000 colonic polyps had pouch adenomas, and 25% of patients with 200 to 1000 colonic polyps had pouch adenomas at follow-up. No relationship was found between ileal pouch adenomas and pouch shape (J, S, or straight ileoanal anastomosis with multiple myotomies) or the APC mutation. Polyps larger than 5 mm were removed by endoscopy or surgery. Ileal pouch adenomas were common after restorative proctocolectomy. Patients >50 years of age and patients with >1000 colonic adenomas at the time of colectomy were more prone to ileal pouch adenomas. The development of malignancy in the terminal ileum can present a fast course and does not seem to follow the classic adenoma-carcinoma sequence.
- 1 March 2012
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 55 (3) , 322-329
Ileal Pouch Adenomas and Carcinomas After Restorative Proctocolectomy for Familial Adenomatous Polyposis
Restorative proctocolectomy and IPAA has become the treatment of choice in familial adenomatous polyposis. However, several cases of adenomas and carcinomas arising in the ileal pouch were reported. The aim of this study was to evaluate the prevalence and natural history of ileal pouch adenomas and the development of carcinomas in patients with restorative proctocolectomy for familial adenomatous polyposis. We prospectively studied patients who underwent IPAA during the past 20 years at the surgical unit of the University of Florence in Italy. We investigated the extent of the risk and the factors that are involved in the development of neoplastic changes of the pouch. Furthermore, because it is not entirely clear when and how polyps should be treated, we have revised our modality of treatment for this unusual pathology. Sixty-nine patients with familial adenomatous polyposis underwent restorative proctocolectomy. In 66 patients, handsewn ileoanal anastomosis with anal canal mucosectomy was performed. After surgery, all patients underwent endoscopic surveillance. After 10 years of follow-up, 1 ileal pouch adenoma was found in 64.9% of restorative proctocolectomy patients, and ileal pouch carcinomas occurred in 2 patients (29 and 59 years old), 3 and 11 years after restorative proctocolectomy. The number of colonic adenomatous polyps influenced the occurrence of pouch adenomas. No patients with 1000 colonic polyps had pouch adenomas, and 25% of patients with 200 to 1000 colonic polyps had pouch adenomas at follow-up. No relationship was found between ileal pouch adenomas and pouch shape (J, S, or straight ileoanal anastomosis with multiple myotomies) or the APC mutation. Polyps larger than 5 mm were removed by endoscopy or surgery. Ileal pouch adenomas were common after restorative proctocolectomy. Patients >50 years of age and patients with >1000 colonic adenomas at the time of colectomy were more prone to ileal pouch adenomas. The development of malignancy in the terminal ileum can present a fast course and does not seem to follow the classic adenoma-carcinoma sequence.
- 1 December 2011
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (12) , S9
Results of Surgical Salvage Treatment of Anal Canal Cancer
- 1 December 2011
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (12) , S9
Results of Surgical Salvage Treatment of Anal Canal Cancer
- 1 December 2011
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (12) , S3-S4
Colorectal Cancer in Crohn's and Ulcerative Colitis: A Comparative Study in 63 Patients
- 1 December 2011
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (12) , S3-S4
Colorectal Cancer in Crohn's and Ulcerative Colitis: A Comparative Study in 63 Patients
- Open Access
- 1 August 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (8) , 1674-1684
Oxidative state and IL-6 production in intestinal myofibroblasts of Crohnʼs disease patients
Intestinal subepithelial myofibroblasts (ISEMFs) produce inflammatory cytokines in response to certain stimuli. In the intestine of patients with Crohn's disease (CD), cytokine synthesis is modified and an increased number of myofibroblasts has been observed. The intracellular redox state influences cytokine production and oxidative stress is present in the intestinal mucosa of CD patients. This study was performed in ISEMFs isolated from the colon of patients with active CD and in a myofibroblast cell line derived from human colonic mucosa: 18Co cells. Cellular glutathione (GSH) levels were modulated by treatment with buthionine sulfoximine, an inhibitor of GSH synthesis, or N-acetylcysteine, a GSH precursor. GSH and oxidized glutathione (GSSG) levels were measured by high-performance liquid chromatography (HPLC) methods. Interleukin (IL)-6 production was detected by enzyme-linked immunosorbent assay (ELISA). ISEMFs of CD patients exhibited an increased oxidative state due to a decrease in the GSH/GSSG ratio, which is related to an increase in basal IL-6 production or is stimulated by tumor necrosis factor alpha (TNFα) or bacterial products. This relationship was also confirmed in 18Co cells. Phosphorylation and activation of ERK1/2 and p38 MAPK, which are signaling factors involved in the IL-6 synthesis, were also increased when there is oxidative stress in ISEMFs. This study shows for the first time in ISEMFs of CD patients an increased production of IL-6 synthesis related to the decrease in the GSH/GSSH ratio, suggesting redox regulation with the involvement of specific kinase activation. The present data shed light on the pathogenesis of inflammatory chronic processes and relapses that occur in this pathology. (Inflamm Bowel Dis 2010;)
- 1 August 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (8) , 1674-1684
Open AccessOxidative state and IL-6 production in intestinal myofibroblasts of Crohnʼs disease patients
Intestinal subepithelial myofibroblasts (ISEMFs) produce inflammatory cytokines in response to certain stimuli. In the intestine of patients with Crohn's disease (CD), cytokine synthesis is modified and an increased number of myofibroblasts has been observed. The intracellular redox state influences cytokine production and oxidative stress is present in the intestinal mucosa of CD patients. This study was performed in ISEMFs isolated from the colon of patients with active CD and in a myofibroblast cell line derived from human colonic mucosa: 18Co cells. Cellular glutathione (GSH) levels were modulated by treatment with buthionine sulfoximine, an inhibitor of GSH synthesis, or N-acetylcysteine, a GSH precursor. GSH and oxidized glutathione (GSSG) levels were measured by high-performance liquid chromatography (HPLC) methods. Interleukin (IL)-6 production was detected by enzyme-linked immunosorbent assay (ELISA). ISEMFs of CD patients exhibited an increased oxidative state due to a decrease in the GSH/GSSG ratio, which is related to an increase in basal IL-6 production or is stimulated by tumor necrosis factor alpha (TNFα) or bacterial products. This relationship was also confirmed in 18Co cells. Phosphorylation and activation of ERK1/2 and p38 MAPK, which are signaling factors involved in the IL-6 synthesis, were also increased when there is oxidative stress in ISEMFs. This study shows for the first time in ISEMFs of CD patients an increased production of IL-6 synthesis related to the decrease in the GSH/GSSH ratio, suggesting redox regulation with the involvement of specific kinase activation. The present data shed light on the pathogenesis of inflammatory chronic processes and relapses that occur in this pathology. (Inflamm Bowel Dis 2010;)
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17, 33-40
Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome: Review of Literature
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17, 33-40
Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome: Review of Literature
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17, 1
Introduction to the 12th International Workshop on Multiple Endocrine Neoplasia
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17, 1
Introduction to the 12th International Workshop on Multiple Endocrine Neoplasia
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17 (4) , 655
Introduction to the 12th International Workshop on Multiple Endocrine Neoplasia
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17 (4) , 655
Introduction to the 12th International Workshop on Multiple Endocrine Neoplasia
- Open Access
- 1 February 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (2) , E6-E7
Single-port laparoscopic access for Crohnʼs disease complicated by enterocutaneous fistula
- 1 February 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (2) , E6-E7
Open AccessSingle-port laparoscopic access for Crohnʼs disease complicated by enterocutaneous fistula